Vertex announces key advancements across kidney portfolio

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced several important advancements across its programs in immunoglobulin a nephropathy (igan), apol1-mediated kidney disease (amkd) and autosomal dominant polycystic kidney disease (adpkd). these updates represent significant progress toward reaching the company's goal of bringing forward first-in-class or best-in-class therapies that target the underlying cause of these serious kidney diseases. povetacicept.
VRTX Ratings Summary
VRTX Quant Ranking